BeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Bump from Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on BeOne Medicines from $459 to $465 and maintained an “outperform” rating, implying 13.76% upside from the share price cited in the report.
• Analyst sentiment is broadly positive: 16 analysts rate the stock a Buy and one a Hold, with a consensus “Moderate Buy” rating and an average price target of $434.79.
• BeOne reported quarterly EPS of $3.64, beating the $2.34 consensus, and revenue of $1.89 billion versus $1.76 billion expected. Shares rose 5.6% on Friday.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its price target increased by research analysts at Royal Bank Of Canada from $459.00 to $465.00 in a report issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective indicates a potential upside of 13.76% from the company's current price.

A number of other research analysts also recently weighed in on the stock. Weiss Ratings upgraded shares of BeOne Medicines from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, October 8th. Nomura increased their price target on BeOne Medicines from $454.75 to $484.91 and gave the company a "buy" rating in a research note on Thursday, August 6th. TD Cowen lifted their price objective on shares of BeOne Medicines from $424.00 to $454.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Barclays upped their target price on BeOne Medicines from $415.00 to $446.00 and gave the stock an "overweight" rating in a report on Friday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an "overweight" rating in a research report on Thursday, October 1st. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, BeOne Medicines currently has a consensus rating of "Moderate Buy" and an average target price of $434.79.

BeOne Medicines Stock Up 5.6%

Shares of BeOne Medicines stock traded up $21.52 during trading on Friday, hitting $408.77. The company's stock had a trading volume of 547,607 shares, compared to its average volume of 318,506. The company has a fifty day simple moving average of $362.80 and a two-hundred day simple moving average of $325.98. BeOne Medicines has a 52 week low of $253.95 and a 52 week high of $409.80. The company has a market capitalization of $44.88 billion, a PE ratio of 72.00 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating the consensus estimate of $2.34 by $1.30. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities research analysts predict that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Activity

In other news, SVP Chan Lee sold 1,115 shares of the firm's stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $375.00, for a total value of $418,125.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 31,028 shares of BeOne Medicines stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $362.97, for a total transaction of $11,262,233.16. Following the sale, the insider directly owned 31,028 shares in the company, valued at approximately $11,262,233.16. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 376,373 shares of company stock worth $134,848,154. 6.19% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of ONC. Fisher Asset Management LLC acquired a new stake in shares of BeOne Medicines during the third quarter worth about $367,000. Russell Investments Group Ltd. raised its holdings in BeOne Medicines by 34.2% during the third quarter. Russell Investments Group Ltd. now owns 29,621 shares of the company's stock worth $10,839,000 after purchasing an additional 7,556 shares in the last quarter. Jefferies Financial Group Inc. lifted its position in BeOne Medicines by 184.4% in the third quarter. Jefferies Financial Group Inc. now owns 18,200 shares of the company's stock valued at $6,660,000 after acquiring an additional 11,800 shares during the last quarter. Knights of Columbus Asset Advisors LLC acquired a new stake in shares of BeOne Medicines in the 3rd quarter valued at about $106,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of BeOne Medicines by 22.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 966 shares of the company's stock worth $340,000 after acquiring an additional 178 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q3 results topped estimates and revenue guidance was raised. BeOne reported adjusted EPS of $3.64 versus the $2.34 consensus and revenue of $1.89 billion versus $1.76 billion expected. The company also raised its 2026 revenue guidance, signaling stronger business expectations. BeOne Q3 earnings and guidance
• Positive Sentiment: FDA granted priority review to a BRUKINSA combination. The review concerns use in first-line mantle cell lymphoma; a label expansion could broaden the drug’s potential market if approved. FDA priority review for BRUKINSA
• Positive Sentiment: Analysts raised their price targets and maintained positive ratings. Barclays lifted its target to $446 with an “overweight” rating; Citizens JMP raised its target to $463 and kept “market outperform”; Wells Fargo raised its target to $435 and retained “overweight.” The revisions reflect improved analyst expectations, though targets are not guarantees of future performance. Barclays rating information Citizens JMP rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.